Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 569

1.

Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.

Barrett JE, Williams JW Jr, Oxman TE, Frank E, Katon W, Sullivan M, Hegel MT, Cornell JE, Sengupta AS.

J Fam Pract. 2001 May;50(5):405-12.

PMID:
11350703
2.

Treatment of dysthymia and minor depression in primary care: A randomized controlled trial in older adults.

Williams JW Jr, Barrett J, Oxman T, Frank E, Katon W, Sullivan M, Cornell J, Sengupta A.

JAMA. 2000 Sep 27;284(12):1519-26.

PMID:
11000645
3.
4.

Status of minor depression or dysthymia in primary care following a randomized controlled treatment.

Oxman TE, Barrett JE, Sengupta A, Katon W, Williams JW Jr, Frank E, Hegel M.

Gen Hosp Psychiatry. 2001 Nov-Dec;23(6):301-10.

PMID:
11738460
5.

Correlates of remission in primary care patients treated for minor depression.

Frank E, Rucci P, Katon W, Barrett J, Williams JW Jr, Oxman T, Sullivan M, Cornell J.

Gen Hosp Psychiatry. 2002 Jan-Feb;24(1):12-9.

PMID:
11814529
6.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
7.

Response styles among patients with minor depression and dysthymia in primary care.

Schmaling KB, Dimidjian S, Katon W, Sullivan M.

J Abnorm Psychol. 2002 May;111(2):350-6.

PMID:
12003456
8.

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.

Eur Neuropsychopharmacol. 2004 Dec;14(6):457-70.

PMID:
15589385
9.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
10.

Predictors of nonresponse to treatment in primary care patients with dysthymia.

Katon W, Russo J, Frank E, Barrett J, Williams JW Jr, Oxman T, Sullivan M, Cornell J.

Gen Hosp Psychiatry. 2002 Jan-Feb;24(1):20-7.

PMID:
11814530
11.

The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.

Ballús C, Quiros G, De Flores T, de la Torre J, Palao D, Rojo L, Gutiérrez M, Casais L, Riesgo Y.

Int Clin Psychopharmacol. 2000 Jan;15(1):43-8.

PMID:
10836286
12.

A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.

Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB.

J Clin Psychiatry. 2006 Feb;67(2):288-96.

PMID:
16566626
13.

Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial.

Lucas M, Asselin G, Mérette C, Poulin MJ, Dodin S.

Am J Clin Nutr. 2009 Feb;89(2):641-51. doi: 10.3945/ajcn.2008.26749. Epub 2008 Dec 30.

15.

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.

Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK.

J Clin Psychiatry. 2001 May;62(5):350-7. Erratum in: J Clin Psychiatry 2001 Aug;62(8):658.

PMID:
11411817
17.

The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression.

Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski P, Walker E, Bush T.

Arch Gen Psychiatry. 2004 Oct;61(10):1042-9.

PMID:
15466678
18.

Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs.

Browne G, Steiner M, Roberts J, Gafni A, Byrne C, Dunn E, Bell B, Mills M, Chalklin L, Wallik D, Kraemer J.

J Affect Disord. 2002 Apr;68(2-3):317-30.

PMID:
12063159
19.

Efficacy of controlled-release paroxetine in the treatment of late-life depression.

Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD.

J Clin Psychiatry. 2003 Sep;64(9):1065-74.

PMID:
14628982
20.

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.

Peveler R, Kendrick T, Buxton M, Longworth L, Baldwin D, Moore M, Chatwin J, Goddard J, Thornett A, Smith H, Campbell M, Thompson C.

Health Technol Assess. 2005 May;9(16):1-134, iii.

Supplemental Content

Support Center